Localized delivery of growth factors for bone repair

被引:299
作者
Luginbuehl, V [1 ]
Meinel, L [1 ]
Merkle, HP [1 ]
Gander, B [1 ]
机构
[1] Swiss Fed Inst Technol, Inst Pharmaceut Sci, Drug Formulat & Delivery Grp, CH-8057 Zurich, Switzerland
关键词
growth factors; bone repair; drug delivery; localized delivery; controlled delivery; release kinetics; dose effects; clinical safety;
D O I
10.1016/j.ejpb.2004.03.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Delivery of growth factors for tissue (e.g. bone, cartilage) or cell repair (e.g. nerves) is about to gain important potential as a future therapeutic tool. Depending on the targeted cell type and its state of differentiation, growth factors can activate or regulate a variety of cellular functions. Therefore, strictly localized delivery regimens at well-defined kinetics appear to be logical prerequisites to assure safe and efficacious therapeutic use of such factors and avoid unwanted side effects and toxicity, a major hurdle in the clinical development of growth factor therapies so far. This review summarizes various approaches for localized growth factor delivery as focused on bone repair. Similar considerations may apply to other growth factors and therapeutic indications. Considering the vast number of preclinical studies reported in the area of growth factor-assisted bone repair, it surprises though that only two medical products for bone repair have so far been commercialized, both consisting of a collagen matrix impregnated with a bone morphogenetic protein. The marked diversity of the reported growth factors, delivery concepts and not yet standardized animal models adds to the complexity to learn from past preclinical studies presented in the literature. Nonetheless, it is now firmly established from the available information that the type, dose and delivery kinetics of growth factors all play a decisive role for the therapeutic success of any such approach. Very likely, all of these parameters have to be adapted and optimized for each animal model or clinical case. In the future, systems for localized growth factor delivery thus need to be designed in such a way that their modular components are readily adaptable to the individual pathology. To make such customized systems feasible, close cooperative networks of biomedical and biomaterials engineers, pharmaceutical scientists, chemists, biologists and clinicians need to be established. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:197 / 208
页数:12
相关论文
共 138 条
[1]   Simple carrier matrix modifications can enhance delivery of recombinant human bone morphogenetic protein-2 for posterolateral spine fusion [J].
Akamaru, T ;
Suh, D ;
Boden, SD ;
Kim, HS ;
Minamide, A ;
Louis-Ugbo, J .
SPINE, 2003, 28 (05) :429-434
[2]   A recombinant human TGF-β1 fusion protein with collagen-binding domain promotes migration, growth, and differentiation of bone marrow mesenchymal cells [J].
Andrades, JA ;
Han, B ;
Becerra, J ;
Sorgente, N ;
Hall, FL ;
Nimni, ME .
EXPERIMENTAL CELL RESEARCH, 1999, 250 (02) :485-498
[3]   DEMONSTRATION OF TGF-BETA-1 MESSENGER-RNA BY INSITU HYBRIDIZATION IN NORMAL HUMAN FRACTURE-HEALING [J].
ANDREW, JG ;
HOYLAND, J ;
ANDREW, SM ;
FREEMONT, AJ ;
MARSH, D .
CALCIFIED TISSUE INTERNATIONAL, 1993, 52 (02) :74-78
[4]   POTENT ECTOPIC BONE-INDUCING ACTIVITY OF BONE MORPHOGENETIC PROTEIN-4/7 HETERODIMER [J].
AONO, A ;
HAZAMA, M ;
NOTOYA, K ;
TAKETOMI, S ;
YAMASAKI, H ;
TSUKUDA, R ;
SASAKI, S ;
FUJISAWA, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1995, 210 (03) :670-677
[5]   LOCAL APPLICATION OF GROWTH-FACTOR IGF-1 TO HEALING BONE - EXPERIMENTS WITH A TITANIUM CHAMBER IN RABBITS [J].
ASPENBERG, P ;
ALBREKTSSON, T ;
THORNGREN, KG .
ACTA ORTHOPAEDICA SCANDINAVICA, 1989, 60 (05) :607-610
[6]   The bone morphogenetic proteins antagonist noggin inhibits membranous ossification [J].
Aspenberg, P ;
Jeppsson, C ;
Economides, AN .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (03) :497-500
[7]   Transforming growth factor beta and bone morphogenetic protein 2 for bone ingrowth: A comparison using bone chambers in rats [J].
Aspenberg, P ;
Jeppsson, C ;
Wang, JS ;
Bostrom, M .
BONE, 1996, 19 (05) :499-503
[8]   Growth factor delivery for tissue engineering [J].
Babensee, JE ;
McIntire, LV ;
Mikos, AG .
PHARMACEUTICAL RESEARCH, 2000, 17 (05) :497-504
[9]   Materials for protein delivery in tissue engineering [J].
Baldwin, SP ;
Saltzman, WM .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 33 (1-2) :71-86
[10]  
Bauer TW, 2000, CLIN ORTHOP RELAT R, P10